Due to familiarity, short half-life, ease of monitoring, and the availability of a reversal agent, heparin remains the anticoagulant of choice for cardiac operations requiring cardiopulmonary bypass (CPB). However, occasionally patients require CPB but should not receive heparin, most often because of acute or subacute heparin-induced thrombocytopenia (HIT). In these cases, if it is not feasible to wait for the disappearance of HIT antibodies, an alternative anticoagulant must be selected. A number of non-heparin anticoagulant options have been explored. However, current recommendations suggest the use of a direct thrombin inhibitor such as bivalirudin. This review describes the use of heparin alternatives for the conduct of CPB with a focus on the direct thrombin inhibitors.
ShantsilaELipGYHChongBH. Heparin-induced thrombocytopenia: a contemporary clinical approach to diagnosis and management. Chest. 2009;135:1651-1664.
2.
LinkinsLADansALMooresLK. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl):e495s-e530s.
3.
WarkentinTE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin. 2011;27:805-823.
NewmanPMChongBH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4 heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182-187.
6.
GreinacherAHoltfreterBKrauelK. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood. 2011;118:1395-1401.
7.
RauovaLPonczMMcKenzieSE. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood
. 2005;105:131-138.
8.
WarkentinTESheppardJAHorsewoodPSimpsonPJMooreJCKeltonJG. Impact of patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
9.
AmiralJPeynaud-DebayleEWolfMBrideyFVissacAMMeyerD. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular weight heparin. Am J Hematol. 1996;52:90-95.
10.
BriegerDBMakKHKottke-MarchantKTopolEJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 1998;31:1449-1459.
11.
PouplardCAmiralJYLaporte-SimitsidisS. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999;111:700-706.
12.
WarkentinTESheppardJIMooreJCMooreKMSigouinCSKeltonJG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?J Lab Clin Med. 2005;146:341-346.
13.
ChanNMalynnEShazBUhlL. Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. Am J Hematol. 2008;83:212-217.
14.
PauznerRGreinacherASellangKAlthausKShenkmanBSeligsohnU. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost. 2009;7:1070-1074.
15.
WarkentinTESheppardJIMooreJCSigouinCSKeltonJG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6:1304-1312.
16.
SheridanDCarterCKeltonJG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
17.
WarkentinTEKeltonJG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
WelsbyIJUmJMilanoCAOrtelTLArepallyG. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg. 2010;110:30-35.
20.
MurphyGSMarymontJH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2007;21:113-126.
21.
WeitzJILeslieBHudobaM. Thrombin binds to soluble fibrin degradation products where it is prothrombosed from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 1998;97:544-552.
22.
WittkowskyAKKondoLM. Lepirudin dosing in dialysis-dependent renal failure. Pharmacotherapy. 2000;20:1123-1128.
23.
KosterAMerkleFHansenR. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg. 2000;91:265-269.
24.
NuttalGAOliverWCSantrachPJ. Patients with a history of type II heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg. 2003;93:344-350.
25.
GreinacherA. Lepirudin for the treatment of heparin-induced thrombocytopenia. In: WarkentinTEGreinacherA, eds. Heparin-Induced Thrombocytopenia. 3rd ed.New York, NY: Marcel Dekker; 2004:397-436.
26.
PotzschBMadlenerKSeeligCRiessCFGreinacherAMüller-BerghausG. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass—assessment of whole-blood ecarin clotting time. Thromb Haemost. 1997;77:920-925.
27.
ParissisH. Lepirudin as an alternative to “heparin allergy” during cardiopulmonary bypass. J Cardiothorac Surg. 2011;6:44.
28.
GreinacherAJanssensUBergG. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia (HAT) Study investigators. Circulation. 1999;100:587-593.
29.
GreinacherAVolpelHJanssensU. Lepirudin provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
30.
LubenowNEichlerPLietzTFarnerBGreinacherA. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood. 2004;104:3072-3077.
31.
KosterAHansenRKuppeHHetzerRCrystalGJMertzlufftF. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a one-year experience in 57 patients. J Cardiothorac Vasc Anesth. 2000;14:243-2248.
32.
GreinacherALubenowNEichlerP. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation. 2003;108:2062-2065.
KosterA. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass grafting. Am J Cardiol. 2004;93:356-359.
35.
CasserlyIPKereiakesDJGreyWA. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res. 2004;113:115-121.
36.
DykeCMSmediraNGKosterA. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533-539.
37.
SmediraNGDykeCMKosterA. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg. 2006;131:686-692.
38.
SalemiAAgarwalYPFontesMA. An assay to monitor bivalirudin levels on cardiopulmonary bypass. Ann Thorac Surg. 2011;92:332-334.
39.
KosterAChewDGrundelMBauerMKuppeHSpiessBD. Bivalirudin monitored with ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg. 2003;96:383-386.
40.
SculliTMMauroVF. Pharmacology and clinical use of bivalirudin. Ann Pharmacother. 2002;36:1028-1041.
41.
AwadHBryantRMalikODimitrovaGSai-SudhakarCB. Thrombosis during off-pump LVAD placement in a patient with heparin-induced thrombocytopenia using bivalirudin. J Cardiothorac Surg. 2013;8:115.
42.
CapodannoDAngiolilloDJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125:2649-2661.
43.
KosterADykeCMAldeaG. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON study. Ann Thorac Surg. 2007;83:572-577.
44.
AgarwalSUllomBAl-BaghdadiYOkumuraM. Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesth Clin Pharm. 2012;28:106-110.
45.
SwanSKHusrtingMJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-329.
46.
FollisFFilipponeGMontalbanoG. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?Interact Cardiovasc Thorac Surg. 2010;10:592-596.
47.
SmithAIStroudRDamianiPVaynblatM. Use of argatroban for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy. Eur J Cardiothorac Surg. 2008;34:1113-1114.
48.
YarbroughPMVarediAWalkerARondinaMT. Argatroban dose reductions for suspected heparin-induced thrombocytopenia complicated by Child-Pugh class C liver disease. Ann Pharmacother. 2012;46:e30.
49.
EdwardsJTHambyJKWorrallNK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg. 2003;75:1622-1624.
50.
FurukawaKOhtekiHHiraharaKNaritaYKogaS. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg. 2001;122:1255-1256.
51.
OhtekiHFurukawaKOhnishiHNaritaYSakaiMDoiK. Clinical experience with argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg. 2000;48:39-46.
52.
NagleELTsuLVDagerWE. Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy. Ann Pharmacother. 2011;45:e47.
53.
KosterAAmin-ParsaMKaufmannM. Fulminate heparin-induced thrombocytopenia and surgery with deep hypothermic circulatory arrest using bivalirudin. Ann Thorac Surg. 2013;95:1075-1081.
54.
GrocottHPRootJBerkowitzSDdeBruijnNLandolfoK. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparanoid, danaparoid-sodium. J Cardiothorac Vasc Anesth. 1997;11:875-877.
55.
CarrierMRobitailleDPerraultLP. Heparin versus danaparoid in off-pump coronary artery bypass grafting: results of a prospective randomized clinical trial. J Thorac Cardiovasc Surg. 2003;125:325-329.
56.
ZulysVJTeasdaleSJMichelER. Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989;71:870-877.
57.
MetzlufftFKuppeHKosterA. Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function. J Cardiothorac Vasc Anesth. 2000;14:304-308.
58.
AntoniouTKapetanakisEITheodorakiK. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum. 2002;5:354-357.
59.
KosterALoebeMMertzlufftFKuppeHHetzerR. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GPIIb/IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg. 2000;70:2160-2161.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
